Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Decisions in HIV Care: Managing Suboptimal CD4+ Cell Count Increase Despite Suppressive ART

Listen as William R. Short, MD, MPH, AAHIVS, discusses the data supporting guideline recommendations about the consequences of suboptimal CD4+ cell count, whether to intensify therapy, switch ART, and more.
William R. Short, MD, MPH, AAHIVS
Released: November 19, 2021

In this episode, William R. Short, MD, MPH, AAHIVS, explores recommendations and data on strategies to address suboptimal CD4+ cell count response in people with HIV on suppressive ART.

Listen as he gives his perspectives on:

  • The consequences of suboptimal CD4+ cell count response
  • ART intensification
  • ART switch strategies with data from the SPIRAL study
  • Data on the addition of interleukin-2 from the SILCAAT and ESPIRIT studies
  • DHHS guideline recommendations

Information on this Educational Activity

Faculty

William R. Short, MD, MPH, AAHIVS

Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

William R. Short, MD, MPH, AAHIVS, has disclosed that he has received fees for non-CME/CE services from Janssen and consulting fees from ViiV.

Program Medium

This program has been made available online.

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Discussion of key considerations for switching antiretroviral therapy when the patient is pregnant, from Clinical Care Options (CCO)

person default Annette Haberl, MD William R. Short, MD, MPH, AAHIVS Released: November 23, 2022

Prof Don Smith discusses new HIV data from IDWeek 2022 on long-acting cabotegravir plus rilpivirine in this commentary from Clinical Care Options (CCO)

Don Smith, MD Released: November 22, 2022

Expert discussion of HIV Glasgow 2022 data on optimizing islatravir dosing based on lymphocyte changes and IDWeek 2022 data on LA CAB + RPV real-world effectiveness in the US OPERA Cohort, from Clinical Care Options (CCO)

Brenda E. Crabtree Ramírez, MD Released: November 22, 2022

Clinical Care Options (CCO) downloadable slides from Drs Joseph Eron, Karine Lacombe, Chloe Orkin, and Babafemi Taiwo on HIV data from IDWeek and HIV Glasgow 2022

Joseph J. Eron, Jr., MD Karine Lacombe, MD, PhD Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Babafemi Taiwo, MBBS Released: November 22, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings